Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24.
No abstract available

Keywords: brentuximab vedotin; primary cutaneous T-cell lymphoma; refractory; relapsed; systemic anaplastic large-cell lymphoma.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Brentuximab Vedotin
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Female
  • France
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immunoconjugates / therapeutic use*
  • Ki-1 Antigen / genetics*
  • Ki-1 Antigen / metabolism
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Lymphoma, T-Cell, Peripheral / genetics*
  • Lymphoma, T-Cell, Peripheral / mortality
  • Lymphoma, T-Cell, Peripheral / pathology
  • Male
  • Middle Aged
  • Pilot Projects
  • Prognosis
  • Recurrence
  • Retrospective Studies
  • Signal Transduction
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin